# ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)

> **NCT02670564** · PHASE4 · UNKNOWN · sponsor: **Swiss Pediatric Oncology Group** · enrollment: 1000 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **GENETIC:** Pharmacogenomics
- **OTHER:** Busulfan plasma level measurements

## Key facts

- **NCT ID:** NCT02670564
- **Lead sponsor:** Swiss Pediatric Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-04
- **Primary completion:** 2021-04
- **Final completion:** 2026-04
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2019-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02670564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02670564, "ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)". Retrieved via MORVS 2026-11-02 from https://api.morvs.ai/clinical/NCT02670564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*